Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

Abstract: This invention relates to treating female sexual arousal disorder and/or improving female sexual response, and related symptoms, preferably with topical prostaglandin compositions.

Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

Abstract: The present invention relates to methods for reconstituting and relates to reconstitution devices suitable for reconstituting many different materials. Furthermore, the present invention includes methods of treatment and methods of use related to a reconstitution device or apparatus. Some embodiments are suitable for reconstituting small amounts of a pharmaceutical compositions and using the pharmaceutical composition for the treatment of sexual dysfunction.

Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

Abstract: Mixing devices and systems are disclosed for storing separate components and for mixing and dispensing those Components on demand. A mixing device includes a syringe having a generally tubular housing formed with a mixing chamber. A plunger is fitted to the tubular housing to form a first syringe. A dispensing syringe is releasably connected to the mixing chamber. At this point each syringe holds a desired amount of a mixture component. The contents of one syringe are passed through the mixing chamber to the other syringe, forming a usually incomplete mixture. The mixture is then passed through the mixing chamber to the other syringe. Multiple passes through the mixing chamber are continued until the desired mixing result is achieved, and the mixture material is contained in the second syringe that is used to thereafter dispense desired amounts of the mixture.

Abstract: Mixing devices and systems are disclosed for storing separate components and for mixing and dispensing those components on demand. A mixing device includes a syringe having a generally tubular housing formed with a mixing chamber. A plunger is fitted to the tubular housing to form a first syringe. A dispensing syringe is releasably connected to the mixing chamber. At this point each syringe holds a desired amount of a mixture component. The contents of one syringe are passed through the mixing chamber to the other syringe, forming a usually incomplete mixture. The mixture is then passed through the mixing chamber to the other syringe. Multiple passes through the mixing chamber are continued until the desired mixing result is achieved, and the mixture material is contained in the second syringe that is used to thereafter dispense desired amounts of the mixture.

Abstract: Mixing devices and systems are disclosed for storing separate components and for mixing and dispensing those components on demand. A mixing device includes a syringe having a generally tubular housing formed with a mixing chamber. A plunger is fitted to the tubular housing to form a first syringe. A dispensing syringe is releasably connected to the mixing chamber. At this point each syringe holds a desired amount of a mixture component. The contents of one syringe are passed through the mixing chamber to the other syringe, forming a usually incomplete mixture. The mixture is then passed through the mixing chamber to the other syringe. Multiple passes through the mixing chamber are continued until the desired mixing result is achieved, and the mixture material is contained in the second syringe that is used to thereafter dispense desired amounts of the mixture.

Abstract: A prostaglandin E composition comprises are substantially free from C1-C4 alcohols and include the prostaglandin E compound together with a (C1-C4)-alkyl(C8-C22)carboxylic ester (e.g., ethyl laurate), an N,N-di(C1-C8)alkylamino substituted, (C4-C18)alkyl(C2-C18)carboxylic ester and/or a pharmaceutically acceptable addition salt thereof, and optionally, a viscosity enhancing agent such as guar gum. The prostaglandin E composition can be combined with an aqueous alcoholic diluent to form a pharmaceutical composition for topical application to a patient, for example, to treat sexual dysfunction. The prostaglandin E compositions are stable for prolonged periods of storage at room temperature.

Abstract: A prostaglandin E composition comprises are substantially free from C1-C4 alcohols and include the prostaglandin E compound together with a (C1-C4)-alkyl (C8-C22) carboxylic ester (e.g., ethyl laurate), an N,N-di(C1-C8) alkylamino substituted, (C4-C18) alkyl (C2-C18) carboxylic ester and/or a pharmaceutically acceptable addition salt thereof, and optionally, a viscosity enhancing agent such as guar gum. The prostaglandin E composition can be combined with an aqueous alcoholic diluent to form a pharmaceutical composition for topical application to a patient, for example, to treat sexual dysfunction. The prostaglandin E compositions are stable for prolonged periods of storage at room temperature.

Abstract: Compounds of prostaglandin E group (PGE compounds) are stabilized as non-aqueous compositions that include the compound together with a bulking agent that can be a non-aqueous liquid or a solid in a sheet, film or powder form. The composition can optionally include a skin penetration enhancer. A non-aqueous, solid dosage form comprises a PGE compound substantially uniformly distributed in a carrier sheet or film.

Abstract: Compounds of prostaglandin E group (PGE compounds) are stabilized as non-aqueous compositions that include the compound together with a bulking agent that can be a non-aqueous liquid or a solid in a sheet, film or powder form. The composition can optionally include a skin penetration enhancer. A non-aqueous, solid dosage form comprises a PGE compound substantially uniformly distributed in a carrier sheet or film.